Drug supercharges radiation in fight against advanced cervical cancer
NCT ID NCT03256916
Summary
This study tested whether adding an oral drug called nelfinavir to standard treatment could help patients with advanced cervical cancer live longer without their cancer returning. 348 patients received either the standard treatment of chemotherapy plus radiation, or that same treatment plus nelfinavir taken beforehand. The goal was to see if nelfinavir makes the radiation work better against the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA CERVIX,STAGE III are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tata Memorial Centre
Mumbai, Maharashtra, 400012, India
Conditions
Explore the condition pages connected to this study.